Biohit Oyj (OHEL:BIOBV) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Biohit Oyj Debt-to-Equity?

Biohit Oyj's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.28 Mil. Biohit Oyj's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.43 Mil. Biohit Oyj's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €9.43 Mil. Biohit Oyj's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biohit Oyj's Debt-to-Equity or its related term are showing as below:

OHEL:BIOBV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.13
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Biohit Oyj was 0.13. The lowest was 0.00. And the median was 0.02.

OHEL:BIOBV's Debt-to-Equity is ranked better than
66.76% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs OHEL:BIOBV: 0.07

Biohit Oyj Debt-to-Equity Historical Data

The historical data trend for Biohit Oyj's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohit Oyj Debt-to-Equity Chart

Biohit Oyj Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.04

0.03

0.13

0.07

Biohit Oyj Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.14	0.13	0.09	0.07

Competitive Comparison of Biohit Oyj's Debt-to-Equity

For the Biotechnology subindustry, Biohit Oyj's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohit Oyj's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohit Oyj's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biohit Oyj's Debt-to-Equity falls into.

Biohit Oyj Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biohit Oyj's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.275	+	0.427)	/	9.425
	=	0.07

Biohit Oyj's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.275	+	0.427)	/	9.425
	=	0.07

Biohit Oyj (OHEL:BIOBV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biohit Oyj Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biohit Oyj's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohit Oyj (OHEL:BIOBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohit Oyj (OHEL:BIOBV) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Laippatie 1, Helsinki, FIN, 00880

Website

https://www.biohithealthcare.com

Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies and service laboratory operations.

Biohit Oyj (OHEL:BIOBV) Headlines

No Headlines